Literature DB >> 22133120

Antinuclear antibodies as ancillary markers in primary biliary cirrhosis.

Alessandro Granito1, Paolo Muratori, Chiara Quarneti, Georgios Pappas, Ronny Cicola, Luigi Muratori.   

Abstract

Antimitochondrial antibodies are the serological hallmark of primary biliary cirrhosis (PBC). Besides antimitochondrial antibodies, the autoantibody profile of PBC includes antinuclear antibodies (ANA) which are detectable by indirect immunofluorescence in up to 50% of PBC patients. Two immunofluorescence patterns are considered 'PBC-specific': the multiple nuclear dots and rim-like/membranous patterns. The target antigens of the multiple nuclear dots pattern have been identified as Sp100 and promyelocytic leukemia protein, whereas the rim-like/membranous pattern is given by autoantibodies recognizing multiple proteins such as gp210, nucleoporin p62 and the lamin B receptor. Other ANA, especially those already known in the rheumatological setting, such as anticentromere, anti-SSA/Ro and anti-dsDNA antibodies, can be frequently found in PBC, often coexisting in the same patient. In this article, we will report on recent progress in the antigenic characterization of ANA in PBC, their detection with both traditional assays and Western blot/ELISA with molecularly defined nuclear antigens, and we will discuss their clinical significance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22133120     DOI: 10.1586/erm.11.82

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  31 in total

1.  Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome.

Authors:  Eirini I Rigopoulou; Kalliopi Zachou; Nikolaos K Gatselis; Georgia Papadamou; George K Koukoulis; George N Dalekos
Journal:  World J Hepatol       Date:  2013-10-27

2.  Anti-nuclear antibody screening using HEp-2 cells.

Authors:  Carol Buchner; Cassandra Bryant; Anna Eslami; Gabriella Lakos
Journal:  J Vis Exp       Date:  2014-06-23       Impact factor: 1.355

Review 3.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

4.  Profile of Hepatobiliary Dysfunction in Hematopoietic Stem Cell Transplant Recipients: Autoimmune Diseases Also Contribute.

Authors:  Linda Beenet
Journal:  J Clin Exp Hepatol       Date:  2021-04-15

Review 5.  COVID-19 and Autoimmune Liver Diseases.

Authors:  Annarosa Floreani; Sara De Martin
Journal:  J Clin Med       Date:  2022-05-10       Impact factor: 4.964

6.  Atypical primary biliary cholangitis results in vanishing bile duct syndrome with cutaneous xanthomas: a case report.

Authors:  Yuebo Jia; Lin Liu; Baocheng Deng; Yu Huang; Jiaqi Zhao; Guang Bai
Journal:  Diagn Pathol       Date:  2022-07-04       Impact factor: 3.196

7.  Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients.

Authors:  Theodoros A Zografos; Nikolaos Gatselis; Kalliopi Zachou; Christos Liaskos; Stella Gabeta; George K Koukoulis; George N Dalekos
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

8.  The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis.

Authors:  Qiannan Sun; Qian Wang; Ning Feng; Yan Meng; Bin Li; Demei Luo; Xiaoqian Shang; Jie Lv; Ahmad Maqsuod Monsaf; Changmin Wang; Xiumin Ma
Journal:  Ann Transl Med       Date:  2019-08

Review 9.  Sex differences associated with primary biliary cirrhosis.

Authors:  Daniel S Smyk; Eirini I Rigopoulou; Albert Pares; Charalambos Billinis; Andrew K Burroughs; Luigi Muratori; Pietro Invernizzi; Dimitrios P Bogdanos
Journal:  Clin Dev Immunol       Date:  2012-05-30

Review 10.  Recent developments in the management of idiopathic cholestatic liver disease.

Authors:  Mohamad H Imam; Emma Weeding; Keith D Lindor
Journal:  Ann Gastroenterol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.